KPV
KPV (Lysine-Proline-Valine)
A small anti-inflammatory tripeptide derived from alpha-MSH that powerfully reduces gut and skin inflammation without causing skin darkening, hormonal changes, or immune suppression.
KPV is a tripeptide composed of just three amino acids: Lysine, Proline, and Valine. It is derived from the tail end of alpha-melanocyte stimulating hormone (alpha-MSH), a neuropeptide that has broad effects on inflammation, skin pigmentation, and immune function. Researchers discovered that the anti-inflammatory activity of alpha-MSH could be traced specifically to this small three-amino-acid sequence at the end of the molecule, meaning KPV delivers similar or even more powerful anti-inflammatory effects compared to the full-length hormone.
What makes KPV particularly valuable is its selectivity. Unlike alpha-MSH or Melanotan peptides, KPV does not stimulate the melanocyte receptors that cause skin darkening. This means you get a clean anti-inflammatory effect without changes to skin pigmentation, and without the hormonal effects on appetite or libido that come with other melanocortin peptides. Its small size allows it to be administered through multiple routes -- by mouth, by subcutaneous injection, or applied directly to the skin.
KPV is being actively researched for inflammatory bowel disease, skin conditions like psoriasis and eczema, wound healing, and systemic inflammation. For people dealing with gut inflammation, autoimmune flares, or chronic inflammatory conditions, KPV offers a targeted approach that modulates rather than suppresses immune function. It is not FDA approved and is currently available only as a research chemical.
How It Works
The primary mechanism of KPV's anti-inflammatory effect centers on its ability to suppress NF-kappa-B activation, which is often described as the master switch for inflammation. When NF-kappa-B turns on inside a cell, it triggers the production of pro-inflammatory signaling molecules including TNF-alpha, IL-1-beta, IL-6, and IL-8. KPV inhibits this activation after being transported inside cells, effectively turning down the volume on the inflammatory response at its source.
Unlike many peptides that work by binding to receptors on the outside of cells, KPV enters cells through a transporter called PepT1. This is the same transporter your gut uses to absorb small peptides from digested food. During inflammatory bowel disease, PepT1 expression is actually increased in the colon, which means the inflamed tissues absorb even more KPV right where it is needed most. This explains why taking KPV by mouth is particularly effective for gut inflammation -- the very tissues that are inflamed are pulling in the medication more aggressively.
KPV also inhibits the MAP kinase inflammatory signaling pathway, providing a second avenue for reducing inflammation that complements the NF-kappa-B inhibition. These effects occur at nanomolar concentrations, meaning very small amounts are effective. Importantly, KPV achieves all of this without binding to melanocortin receptors, so there are no effects on skin color, appetite, or sexual function.
Potential Benefits
Gut Health and Inflammatory Bowel Disease
This is the most extensively researched application for KPV. It reduces intestinal inflammation in colitis models, protects and repairs the gut barrier, decreases pro-inflammatory signaling molecule production in the colon, supports mucosal healing, and shows potential for ulcerative colitis and Crohn's disease. The fact that inflamed gut tissue actively absorbs more KPV through the PepT1 transporter makes oral administration particularly effective.
Skin Health
KPV reduces inflammation in psoriasis, eczema, and dermatitis. It accelerates wound healing, decreases redness and irritation, and promotes tissue repair without scarring. Critically, it does not cause skin pigmentation changes unlike other alpha-MSH-derived compounds, making it safe for cosmetic skin applications.
Antimicrobial Activity
KPV retains antimicrobial properties from its parent molecule alpha-MSH, showing direct activity against Staphylococcus aureus and Candida albicans. It enhances rather than reduces pathogen killing by neutrophils, which means it fights infection while simultaneously reducing harmful inflammation -- a combination most anti-inflammatory drugs cannot achieve.
Systemic Inflammation
Beyond gut and skin applications, KPV may benefit autoimmune conditions, arthritis, and allergic asthma. It modulates the immune response without suppressing it, reduces oxidative stress, and works through fundamental inflammatory pathways that are involved in many different conditions throughout the body.
Wound Healing
KPV speeds wound closure, reduces scar formation, supports proper collagen organization, and has shown effectiveness in burns and chronic ulcers. These wound healing properties complement its anti-inflammatory effects, as excessive inflammation is one of the main barriers to efficient wound healing.
What the Research Shows
A landmark 2008 study by Dalmasso and colleagues published in Gastroenterology showed that nanomolar concentrations of KPV inhibit NF-kappa-B and MAP kinase pathways through the PepT1 transporter rather than melanocortin receptors. Oral KPV reduced colitis severity in two different mouse models of inflammatory bowel disease and decreased the production of pro-inflammatory signaling molecules. This study established the molecular mechanism and demonstrated that oral administration is effective for gut inflammation.
Xiao and colleagues published a 2017 study in Molecular Therapy that developed hyaluronic acid-functionalized nanoparticles loaded with KPV for targeted oral delivery to colitis tissue. The nanoparticle system combined accelerated mucosal healing with reduced inflammation and enhanced the therapeutic efficacy of KPV beyond what the plain peptide achieved. A comprehensive 2008 review by Brzoska and colleagues confirmed that KPV exerts similar or even more pronounced anti-inflammatory activity than full-length alpha-MSH and was effective in animal models of contact dermatitis, arthritis, colitis, and asthma.
Early discovery work by Hiltz and Lipton published in the FASEB Journal in 1989 first demonstrated the anti-inflammatory activity of the C-terminal alpha-MSH fragment and established KPV as the active anti-inflammatory sequence. Antimicrobial studies have also shown that KPV retains antimicrobial properties from its parent molecule alpha-MSH, with activity against Staphylococcus aureus and Candida albicans, and the ability to enhance rather than reduce pathogen killing by immune cells.
What to Know
KPV has an excellent safety profile with minimal reported side effects. Mild injection site irritation may occur with subcutaneous use, transient skin redness can happen with topical application, and occasional stomach upset may arise at higher oral doses. The compound is generally well tolerated across all routes of administration.
KPV offers significant advantages over traditional anti-inflammatory drugs. It does not suppress immune function like steroids, carries no NSAID-related gut or cardiovascular risks, does not cause skin pigmentation changes unlike alpha-MSH, and has no hormonal effects on appetite or libido. However, most research to date is preclinical, and long-term safety in humans has not been fully established.
Pregnant or breastfeeding women should avoid KPV due to insufficient safety data. Individuals with autoimmune conditions or those taking immunosuppressive medications should consult a healthcare provider before use. Those with active malignancy should use with care. Clinical oversight is recommended for all use.
Research References
PepT1-Mediated Tripeptide KPV Uptake Reduces Intestinal Inflammation
Dalmasso G, Charrier-Hisamuddin L, Nguyen HTT, et al. · Gastroenterology · 2008
Landmark study demonstrating that nanomolar concentrations of KPV inhibit NF-kappa-B and MAP kinase pathways through PepT1 transporter uptake, reducing colitis severity in two mouse models and establishing the mechanistic basis for oral KPV in gut inflammation.
View StudyOrally Targeted Delivery of Tripeptide KPV via Hyaluronic Acid-Functionalized Nanoparticles Efficiently Alleviates Ulcerative Colitis
Xiao B, Xu Z, Viennois E, et al. · Molecular Therapy · 2017
Advanced oral delivery study showing hyaluronic acid nanoparticles loaded with KPV provided targeted delivery to colitis tissue, combining accelerated mucosal healing with reduced inflammation and enhanced therapeutic efficacy.
View StudyAntiinflammatory activity of a COOH-terminal fragment of the neuropeptide alpha-MSH
Hiltz ME, Lipton JM · FASEB Journal · 1989
Early discovery work demonstrating the anti-inflammatory and anti-pyretic activity of the C-terminal alpha-MSH fragment, establishing KPV as the active anti-inflammatory sequence of the parent molecule.
View StudyAlpha-Melanocyte-Stimulating Hormone and Related Tripeptides: Biochemistry, Antiinflammatory and Protective Effects In Vitro and In Vivo
Brzoska T, Luger TA, Maaser C, et al. · Endocrine Reviews · 2008
Comprehensive review confirming KPV exerts similar or more pronounced anti-inflammatory activity than full-length alpha-MSH, with effectiveness in animal models of contact dermatitis, arthritis, colitis, and asthma, and a low toxicity profile.
View StudyAlpha-MSH related peptides: a new class of anti-inflammatory and immunomodulating drugs
Luger TA, Brzoska T · Annals of the Rheumatic Diseases · 2007
Reviewed alpha-MSH related peptides including KPV as a new class of anti-inflammatory and immunomodulating drugs with potential applications in rheumatic and inflammatory diseases.
View Study